ABIONYX Pharma reports liquidity account status for H1 2026

1 min read | Published on 07 Jul 2026, 01:29 AM |Updated on 07 Jul 2026, 01:29 AM

Reviewed by

Shriram SScanX News Team

Key Highlights

ABIONYX Pharma reported that its liquidity account, managed by TP ICAP (Europe) SA, held 118,866 shares and €96,894.38 as of June 30, 2026. During H1 2026, the provider purchased 282,460 shares for €933,897.51 and sold 226,618 securities for €782,823.64.

*this image is generated using AI for illustrative purposes only.

ABIONYX Pharma has disclosed the status of its liquidity agreement with TP ICAP (Europe) SA for the first half of 2026. As of June 30, 2026, the liquidity account held 118,866 shares and a cash balance of €96,894.38.

During the first half of 2026, the liquidity provider executed 361 purchase transactions for a total of 282,460 shares, amounting to €933,897.51. Sales activity included 283 transactions involving 226,618 securities, generating €782,823.64.

Liquidity Account Status

The following table details the assets held in the liquidity account at key dates:

Date	Number of Shares	Cash Balance
June 30, 2026	118,866	€96,894.38
December 31, 2025	63,024	€257,777.69
Establishment	131,000	€40,801.20

Transaction Summary H1 2026

Type	Number of Securities	Capital (€)	Transactions
Purchases	282,460	933,897.51	361
Sales	226,618	782,823.64	283

The liquidity agreement was established with an initial allocation of 131,000 shares and €40,801.20 in cash. The half-yearly balance sheet dated December 31, 2025, previously recorded 63,024 shares and €257,777.69 in the cash account.

How might the current liquidity levels impact ABIONYX Pharma's ability to execute future strategic initiatives?

What trends in the transaction volume could indicate about investor sentiment for the remainder of 2026?

Could the shift in the liquidity account's cash balance signal a change in the company's capital allocation strategy?

ABIONYX Pharma secures €33m funding for sepsis trial

1 min read | Published on 01 Jul 2026, 12:56 AM |Updated on 01 Jul 2026, 12:56 AM

Reviewed by

Suketu GScanX News Team

Add as a preferred
source on Google

Key Highlights

ABIONYX Pharma has secured €33 million in funding, extending its financial visibility to the end of 2028. The company will launch a pivotal Phase 2b trial for CER-001 in sepsis by late 2026 and seek EMA approval for LCAT deficiency in early 2028. All shareholder resolutions were approved at the recent Combined General Meeting.

*this image is generated using AI for illustrative purposes only.

ABIONYX Pharma has secured funding totaling up to €33 million, providing financial visibility through the end of 2028 to support its strategic objectives. The company is entering a new phase of development focused on clinical execution and the monetization of its proprietary apoA-I-based technology platform. This financial strength allows ABIONYX Pharma to fully prioritize the development of CER-001 for sepsis and LCAT deficiency.

At the Combined General Meeting held at the company’s headquarters, all resolutions presented by the Board of Directors were adopted. The minutes and voting results will be available on the Company’s website. The company’s value creation strategy will now rely primarily on the quality of clinical data generated and the progressive monetization of its scientific platform.

Strategic Milestones and Funding Allocation

The secured capital will drive several key initiatives aimed at establishing CER-001 as a new standard of care. The company has outlined a clear timeline for its priority programs, which include clinical trials, regulatory submissions, and the development of new partnerships.

Program	Objective	Timeline
CER-001 for sepsis	Initiate pivotal Phase 2b clinical trial	By end of 2026
CER-001 for sepsis	First results expected	First half of 2028
CER-001 for LCAT deficiency	Validation of two GMP batches	2027
CER-001 for LCAT deficiency	Marketing authorization application to EMA	Early 2028

Focus on Execution and Platform Optimization

The Board of Directors and management are prioritizing rigorous execution of the announced programs. Key focus areas include adherence to clinical and GMP production timelines, generating data to support regulatory approvals, and maintaining rigorous financial management. ABIONYX Pharma will also actively pursue collaborations with academic, industrial, and technology partners to accelerate the commercialization of its recombinant apoA-I-based technology platform.

The company’s next financial press release, detailing the cash position and an update on Q2 2026 activity, is scheduled for August 27, 2026.

What specific criteria will ABIONYX use to identify potential partners for the monetization of its apoA-I-based technology platform?

How will the company manage its financial runway if the Phase 2b sepsis trial results are delayed beyond the first half of 2028?

What regulatory precedents in the sepsis space might influence the EMA's review of the CER-001 marketing authorization application?